They are doing a trial in China via EOC pharma, any approval in China is likely to come off the back of this trial.
if anything, approval will be sought in Europe as this was always the intended market for approval with AIPAC. The distribution of results needs to widen as much as possible for the combo arm to trend towards statistical significance.
Ann: Immutep achieves Fast Track designation for Efti from US FDA, page-68
-
- There are more pages in this discussion • 1 more message in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
31.0¢ |
Change
0.020(6.90%) |
Mkt cap ! $450.9M | |||
| Open | High | Low | Value | Volume |
| 29.0¢ | 31.5¢ | 29.0¢ | $1.805M | 5.903M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 193400 | 30.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 31.0¢ | 1000 | 1 |
View Market Depth
| Last trade - 16.10pm 11/11/2024 (20 minute delay) ? |
| IMM (ASX) Chart |